FLT3 and acute myeloid leukemia: Altered metabolomics and dysregulated miRNA profiles are characteristics observed in FLT3-ITD AML patients (Wallace and O'Connell, 2017; Lo Presti et al., 2021; Kreitz et al., 2019; Musharraf et al., 2016; Wang et al., 2019; Xiong et al., 2022).